Hanu Tyagi

Hanu Tyagi

PhD Candidate
Supply Chain & Operations



  • Ph.D. 2024 (Expected)
    Supply Chain and Operations, Carlson School of Management, University of Minnesota - Twin Cities
  • Post-Graduate Programme in Management 2013
    Management, Indian School of Business, Hyderabad (India)
  • Bachelor of Technology 2008
    Mechanical Engineering, National Institute of Technology, Warangal (India)


  • Empirical Pharmaceutical Operations
  • Innovation & New product development
  • Shortages and stockouts
  • Supply chain transparency


I am a fifth-year Ph.D. candidate in the Supply Chain and Operations department at the Carlson School of Management, University of Minnesota. I study tensions between operational outcomes in pharmaceutical supply chains such as novelty, quality and safety, availability, and equity and inclusion. In my dissertation, I examine how transparency inhibits drug novelty (essay 1), expedited approvals impact drug safety (essay 2), and quality failures impact drug availability (essay 3). I compile unique datasets and use empirical research methods to generate insights for operations management theory, practice, and policymakers in the pharmaceutical industry.

Before joining the Ph.D. program, I worked as a Research Associate at the Indian School of Business, Hyderabad (India). Before entering academia, I worked as a management consultant at EY-Parthenon (Dubai, UAE) and ZS Associates (Pune, India). I also worked in the management trainee program at Ranbaxy Labs. Ltd (Gurgaon, India). I have a Post-Graduate Programme in Management from the Indian School of Business, Hyderabad (India), and a Bachelor of Technology from the National Institute of Technology, Warangal (India).

On the personal front, I am a traveler, a hiking/trekking enthusiast, and an open-water scuba diver. I am also an avid music lover who is learning Hindustani classical singing.

Selected Works & Activities

  • Journal Articles
    Deo, S., H. Tyagi, C. Chatterjee, H. Molakapuri. 2019. Did India's price control policy for coronary stents create unintended consequences? Social Science & Medicine 246, 112737
  • Journal Articles
    H. Tyagi, M. Sabharwal, N. Dixit, A. Pal, S. Deo. 2020. Leveraging providers' preferences to customize instructional content: A retrospective analysis of a mobile phone-based intervention. JMIR mHealth and uHealth 8 (3), e15998
  • Conference Proceedings
    Tyagi, H., Hermosilla, M., & Shah, R. (2023). How does Transparency Impact Technological Novelty? Evidence from Large Pharmaceutical Firms. In Academy of Management Proceedings (Vol. 2023, No. 1, p. 13909). Briarcliff Manor, NY: Academy of Management
  • Conference Proceedings
    V Heitlage, JF Farley, R Shah, H Tyagi, D Stenehjem. 2022. EPH138 Post-Marketing Adverse Events of Oncology Medications with Breakthrough Therapy Designation Correlated with Time on Market and Market Share. Value in Health 25 (7), S460

Edit This Page

Edit Profile